Granules India has made a landmark entry by acquiring Senn Chemicals AG, a Swiss-headquartered Contract Development and Manufacturing Organization (CDMO) with expertise in peptides. This strategic acquisition places Granules India in the fast-growing peptide therapeutics space, boosting its capabilities in next-generation therapeutics.
-
Acquisition Details: The transaction was acquired at CHF 20 million (around ₹192 crore) and is anticipated to close in the first half of 2025, pending approvals from regulatory authorities.
-
CDMO Capabilities: Senn Chemicals offers knowledge in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS) with a robust CDMO business and long-standing customer relations across pharmaceutical, cosmetic, and theragnostic segments.
-
Market Expansion: The acquisition fits into Granules India's strategic vision to venture into the peptide-based anti-diabetic and anti-obesity space, specifically in GLP-1 receptor agonists. It adds Granules' global presence by tapping into Senn's European presence and capabilities.
-
Future Plans: Granules and Senn have been working on two GLP-1 based APIs, with plans to increase the number of peptide-based APIs in their portfolio through Senn's R&D capabilities.
Source: Business Standard, YourStory, Pharma Industrial India